Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lintuzumab (Primary) ; Cytarabine; Etoposide; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use

Most Recent Events

11 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight

Ask the expert

Thank you

At a glance

Most Recent Events

You need to be a logged in or subscribed to view this content Request demo

Table of Contents